Literature DB >> 1261756

Quinidine hypersensitivity and liver involvement. A survey of 32 patients.

D Geltner, T Chajek, D Rubinger, I S Levij.   

Abstract

Thirty-two of 487 patients who received quinidine between the years of 1970 and 1974 in the departments of medicine at Hadassah University Hospital developed hypersensitivity reactions. Ten of the 32 patients had clinical and biochemical manifestations of liver invlovement. In 4 patients liver biopsy showed granulomatous hepatitis. It is therefore concluded that quinidine-induced hepatitis is a relatively common side effect of this drug.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261756

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Granulomas and cholestatic--hepatocellular injury associated with phenylbutazone. Report of two cases.

Authors:  K G Ishak; J P Kirchner; J K Dhar
Journal:  Am J Dig Dis       Date:  1977-07

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Unusual hepatotoxic reaction to quinidine.

Authors:  D B Hogan; J Morin; R G Crilly
Journal:  Can Med Assoc J       Date:  1984-04-15       Impact factor: 8.262

4.  Drug effects on the liver: a tabular compilation of drugs and drug-related hepatic diseases.

Authors:  J Ludwig
Journal:  Dig Dis Sci       Date:  1979-10       Impact factor: 3.199

Review 5.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

6.  Trouble Spotted in the Liver!

Authors:  Wa'el Tuqan; Khaldoon Khirfan; Joshua Hanson; Joseph Alcorn
Journal:  Dig Dis Sci       Date:  2016-08       Impact factor: 3.487

Review 7.  Diagnosis of hepatic granulomas: a review.

Authors:  P R Mills; R I Russell
Journal:  J R Soc Med       Date:  1983-05       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.